Clinical trial

MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)

NCT05183074

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2021-02-01

PhaseNA

Study timeline

Study start (actual)2021-02-01Date precision: day

Registry last updated2025-12-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Radiotherapy Side Effectunresolved

Magnetic Resonance-linacunresolved

Stereotactic Ablative RTunresolved

Adaptive Radiotherapyunresolved

Localised Diseaseunresolved

Oligometastatic Diseaseunresolved

Interventions

Sponsors & collaborators

Cancer Institute and Hospital, Chinese Academy of Medical Scienceslead sponsor

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05183074 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.